The AHR Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the aryl hydrocarbon receptor (AHR) gene in the HAP1 cell line. This product provides a loss-of-function model that is valuable for investigating AHR-mediated signaling pathways and their roles in xenobiotic metabolism, immune modulation, and cellular homeostasis. The polyclonal nature of the knockout population ensures representation of diverse editing events, avoiding the clonal bias often associated with single-cell-derived lines. Researchers can use this model to study the consequences of AHR ablation in a near-haploid genetic background that is particularly amenable to functional genomics and pharmacological screening.
HAP1 is a near-haploid human fibroblast-like cell line originally derived from a patient with chronic myeloid leukemia. As an adherent cell line with a haploid karyotype for most chromosomes, HAP1 offers distinct advantages for genetic manipulation and phenotypic analysis, including simplified gene-editing workflows and straightforward interpretation of knockout phenotypes. The haploid nature minimizes genetic redundancy, enabling more penetrant functional readouts in pooled knockout populations. Widely employed in genome-wide screening campaigns, HAP1 cells serve as a robust platform for dissecting gene function in pathways relevant to cancer biology, toxicology, and immunology.
AHR functions as a ligand-activated transcription factor that resides in the cytoplasm in a complex with HSP90, XAP2, and p23. Upon binding to ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 6-formylindolo[3,2-b]carbazole (FICZ), or dietary flavonoids, AHR translocates to the nucleus, where it heterodimerizes with the aryl hydrocarbon receptor nuclear translocator (ARNT). This complex then binds to xenobiotic response elements (XREs) in the promoters of target genes, driving the expression of phase I metabolizing enzymes including CYP1A1 and CYP1B1, as well as immune modulators such as IL-22 and IL-17. Transcriptional activation is fine-tuned by negative regulators like the AHR repressor (AHRR). Through these interactions, AHR coordinates detoxification responses and influences T-cell differentiation and inflammatory processes.
Disruption of AHR in the HAP1 background eliminates the cell??s capacity to induce canonical xenobiotic-metabolizing enzymes and immune effectors, establishing a clean loss-of-function system for mechanistic studies. The near-haploid genome facilitates unambiguous interpretation of gene-disruption effects, especially when combined with assays that measure downstream transcriptional responses or metabolic competence. This model is especially suited to explore how AHR integrates environmental signals with cellular fate decisions, including proliferation, apoptosis, and cytokine production. Moreover, the knockout enables systematic investigation of AHR??s non-canonical roles, such as its involvement in cell cycle regulation and ubiquitin-mediated protein degradation.
Typical applications include toxicological screening where the knockout cells are challenged with TCDD or other xenoestrogens to quantify altered viability or CYP1A1 induction measured by RT-qPCR and Western blotting. In immunology research, AHR disruption allows dissection of IL-22 and IL-17 expression profiles via flow cytometry or ELISA following immune stimuli. The XRE-luciferase reporter assay is a powerful tool to directly assess AHR transcriptional activity, while immunofluorescence can track AHR protein localization changes upon ligand exposure. Given the relevance of AHR in lung, breast, and liver cancers, the knockout cells are also employed to study tumor cell metabolism and drug resistance. For additional technical information, please contact Ascent Research.
